Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 2
1983 4
1987 1
1988 2
1989 1
1990 2
1991 3
1992 6
1993 20
1994 26
1995 28
1996 45
1997 22
1998 47
1999 29
2000 47
2001 70
2002 92
2003 82
2004 76
2005 102
2006 117
2007 147
2008 118
2009 140
2010 186
2011 231
2012 246
2013 286
2014 294
2015 322
2016 318
2017 446
2018 548
2019 450
2020 338
2021 328
2022 234
2023 186
2024 51

Text availability

Article attribute

Article type

Publication date

Search Results

5,249 results

Results by year

Filters applied: . Clear all
Page 1
A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
Chia CSB. Chia CSB. ChemMedChem. 2022 Jun 3;17(11):e202200032. doi: 10.1002/cmdc.202200032. Epub 2022 Apr 5. ChemMedChem. 2022. PMID: 35384350 Review.
Antibody-drug conjugates (ADCs) have emerged as a promising class of biologics since the first approval of Gemtuzumab ozogamicin in 2000. ...
Antibody-drug conjugates (ADCs) have emerged as a promising class of biologics since the first approval of Gemtuzumab ozogamic …
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021.
Agrawal S, Arora S, Amiri-Kordestani L, de Claro RA, Fashoyin-Aje L, Gormley N, Kim T, Lemery S, Mehta GU, Scott EC, Singh H, Tang S, Theoret MR, Pazdur R, Kluetz PG, Beaver JA. Agrawal S, et al. JAMA Oncol. 2023 Feb 1;9(2):266-272. doi: 10.1001/jamaoncol.2022.5985. JAMA Oncol. 2023. PMID: 36580315 Clinical Trial.
IMPORTANCE: Single-arm trials have allowed for transformative therapies to be made available to patients expeditiously. However, using single-arm trials to support drug approval presents several challenges that must be carefully considered. ...In the appropriate con …
IMPORTANCE: Single-arm trials have allowed for transformative therapies to be made available to patients expeditiously. However, using singl …
Trends in kinase drug discovery: targets, indications and inhibitor design.
Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. Attwood MM, et al. Nat Rev Drug Discov. 2021 Nov;20(11):839-861. doi: 10.1038/s41573-021-00252-y. Epub 2021 Aug 5. Nat Rev Drug Discov. 2021. PMID: 34354255 Review.
The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology area and beyond. ...We also discuss trends in kinase inhibitor design, including the …
The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer therapy and heralded the emergence of kinase i …
Trends in the approval of cancer therapies by the FDA in the twenty-first century.
Scott EC, Baines AC, Gong Y, Moore R Jr, Pamuk GE, Saber H, Subedee A, Thompson MD, Xiao W, Pazdur R, Rao VA, Schneider J, Beaver JA. Scott EC, et al. Nat Rev Drug Discov. 2023 Aug;22(8):625-640. doi: 10.1038/s41573-023-00723-4. Epub 2023 Jun 21. Nat Rev Drug Discov. 2023. PMID: 37344568 Review.
The cancer treatment landscape has changed dramatically since the turn of the century, resulting in substantial improvements in outcomes for patients. This Review summarizes trends in the approval of oncology therapeutic products by the United States Food and Drug A …
The cancer treatment landscape has changed dramatically since the turn of the century, resulting in substantial improvements in outcomes for …
Accelerating safe drug development: an ideal approach to approval.
Grever MR. Grever MR. Hematology Am Soc Hematol Educ Program. 2013;2013:24-9. doi: 10.1182/asheducation-2013.1.24. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319158 Review.
Continued investment in the modern era of drug discovery and development will focus on targeted therapies. ...Drug discovery and development are complex and expensive, so efficiency and cooperation in task completion must be tracked....
Continued investment in the modern era of drug discovery and development will focus on targeted therapies. ...Drug disc …
Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development.
Oliveira LJC, Gongora ABL, Jardim DLF. Oliveira LJC, et al. Curr Oncol Rep. 2020 Jun 12;22(7):70. doi: 10.1007/s11912-020-00928-5. Curr Oncol Rep. 2020. PMID: 32529490 Review.
Although the first wave of approvals included advanced cancers, localized disease is under growing interest in recent trials and approvals. Several of these agents are migrating from a monotherapy strategy to combinations (especially with targeted agents and chemoth …
Although the first wave of approvals included advanced cancers, localized disease is under growing interest in recent trials and approvals. …
Drug development and clinical trials--the path to an approved cancer drug.
Rubin EH, Gilliland DG. Rubin EH, et al. Nat Rev Clin Oncol. 2012 Feb 28;9(4):215-22. doi: 10.1038/nrclinonc.2012.22. Nat Rev Clin Oncol. 2012. PMID: 22371130 Review.
Innovative preclinical and clinical approaches, such as the use of advanced genomic technologies, as well as branched adaptive clinical trial designs, have the potential to accelerate the development and approval of highly effective oncology drugs, along with a matc …
Innovative preclinical and clinical approaches, such as the use of advanced genomic technologies, as well as branched adaptive clinical tria …
Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment.
Gyawali B, Hwang TJ, Vokinger KN, Booth CM, Amir E, Tibau A. Gyawali B, et al. Am Soc Clin Oncol Educ Book. 2019 Jan;39:374-387. doi: 10.1200/EDBK_242229. Epub 2019 May 17. Am Soc Clin Oncol Educ Book. 2019. PMID: 31099613 Free article.
Historically, patient experience, including symptomatic toxicities, physical function, and disease-related symptoms during treatment or their perspectives on clinical trials, has played a secondary role in cancer drug development. Regulatory criteria for drug …
Historically, patient experience, including symptomatic toxicities, physical function, and disease-related symptoms during treatment or thei …
Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
Blumenthal GM, Goldberg KB, Pazdur R. Blumenthal GM, et al. Clin Pharmacol Ther. 2017 May;101(5):572-574. doi: 10.1002/cpt.623. Epub 2017 Apr 4. Clin Pharmacol Ther. 2017. PMID: 28074476 Review.
As a result of enhanced understanding of genetic and immunologic underpinnings of cancer, there has been progress in development of targeted and immunotherapies in oncology. The traditional linear sequential model of drug development has evolved. Early clinic …
As a result of enhanced understanding of genetic and immunologic underpinnings of cancer, there has been progress in development of t …
5,249 results